AUTHOR=Kwak Heechun , Kim Min-Soo , Kim Suyong , Kim Jiyoung , Aoki Yasunori , Chung Suk-Jae , Nam Hyun-Ja , Lee Wooin 

TITLE=Kinetic modeling of the plasma pharmacokinetic profiles of ADAMTS13 fragment and its Fc-fusion counterpart in mice

JOURNAL=Frontiers in Pharmacology

VOLUME=15

YEAR=2024

URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1352842

DOI=10.3389/fphar.2024.1352842

ISSN=1663-9812

ABSTRACT=<p><bold>Introduction:</bold> Fusion of the fragment crystallizable (Fc) to protein therapeutics is commonly used to extend the circulation time by enhancing neonatal Fc-receptor (FcRn)-mediated endosomal recycling and slowing renal clearance. This study applied kinetic modeling to gain insights into the cellular processing contributing to the observed pharmacokinetic (PK) differences between the novel recombinant ADAMTS13 fragment (MDTCS) and its Fc-fusion protein (MDTCS-Fc).</p><p><bold>Methods:</bold> For MDTCS and MDTCS-Fc, their plasma PK profiles were obtained at two dose levels following intravenous administration of the respective proteins to mice. The plasma PK profiles of MDTCS were fitted to a kinetic model with three unknown protein-dependent parameters representing the fraction recycled (FR) and the rate constants for endocytosis (k<sub>up</sub>, for the uptake into the endosomes) and for the transfer from the plasma to the interstitial fluid (k<sub>pi</sub>). For MDTCS-Fc, the model was modified to include an additional parameter for binding to FcRn. Parameter optimization was done using the Cluster Gauss-Newton Method (CGNM), an algorithm that identifies multiple sets of approximate solutions (“accepted” parameter sets) to nonlinear least-squares problems.</p><p><bold>Results:</bold> As expected, the kinetic modeling results yielded the FR of MDTCS-Fc to be 2.8-fold greater than that of MDTCS (0.8497 and 0.3061, respectively). In addition, MDTCS-Fc was predicted to undergo endocytosis (the uptake into the endosomes) at a slower rate than MDTCS. Sensitivity analyses identified the association rate constant (k<sub>on</sub>) between MDTCS-Fc and FcRn as a potentially important factor influencing the plasma half-life <italic>in vivo</italic>.</p><p><bold>Discussion:</bold> Our analyses suggested that Fc fusion to MDTCS leads to changes in not only the FR but also the uptake into the endosomes, impacting the systemic plasma PK profiles. These findings may be used to develop recombinant protein therapeutics with extended circulation time.</p>